Oncology Peer Review On-The-Go: 1-on-1 with Dr. Xu Ji: Mental Health Among Cancer Survivors

Podcast

In the newest episode of Oncology Peer Review On-The-Go, CancerNetwork speaks with Xu Ji, PhD, MSPH, of the Winship Cancer Institute about her research on the topic of adult cancer survivorship and mental health.

In this episode of Oncology Peer Review On-The-Go, CancerNetwork speaks 1-on-1 with Xu Ji, PhD, MSPH, of the Winship Cancer Institute regarding her research entitled "Mental Health Among Nonelderly Adult Cancer Survivors: A National Estimate."

Subscribe to the Oncology Peer Review On-The-Go podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Ronald Bleday, MD, credits a chronic pain clinic for consulting patients who may be at a greater risk for prolonged opioid use following surgery.
4 experts in this video
Related Content
Findings from the KRYSTAL-12 trial support adagrasib as a treatment option for those with disease progression on prior chemotherapy and immunotherapy.

Adagrasib Boosts PFS, Responses vs Docetaxel in KRAS G12C+ NSCLC

Russ Conroy
August 16th 2025
Article
Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 16th 2025
Podcast
In June 2025, the FDA approved pembrolizumab in the same indication for HNSCC.2

Health Canada Approves Pembrolizumab/Surgery in Locally Advanced HNSCC

Tim Cortese
August 16th 2025
Article
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 16th 2025
Podcast
Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With Cancer

Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With Cancer

Viviana Cortiana, MS4;Maduri Balasubramanian, MD;Jade Gambill, BS;Diksha Mahendru, MD;Kennedy Itodo, MD;Chandler H. Park, MD, MS, FACP;Yan Leyfman, MD
August 16th 2025
Article
It was noted that in those with a CTFI of more than 3 months but less than or equal to 6 months, a “promising” number of durable responses was observed.

Anlotinib/Irinotecan Shows Promise, Durable Responses in ES-SCLC

Tim Cortese
August 16th 2025
Article